Navigation Links
Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Date:1/5/2009

MADISON, N.J., Jan. 5 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on Wednesday, January 7, 2009 at 8:05 a.m. Eastern Time. Presenting for Wyeth will be Bernard Poussot, Chairman, President and Chief Executive Officer.

Wyeth's presentation will be webcast live for investors at www.wyeth.com and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodi
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... Interleukin Genetics, Inc. (OTCQB: ILIU) announced today ... Thursday, November 10 at 4:30 p.m. (EST) to discuss the ... call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast ... the Investors section of Interleukin Genetics, Inc.,s Website at ...
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... gastroenterology markets, today announced third quarter 2011 financial results. ... September 30, 2011, net revenue was $13.1 million, up from ... net revenue was driven by an increase in sales of ...
... NEW YORK, Nov. 3, 2011 Reportlinker.com announces ... in its catalogue: Global ... http://www.reportlinker.com/p0619270/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory INTRODUCTION  ... BCC,s goal for this study ...
Cached Biology Technology:Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:5/23/2013)... microbial pathogens are growing increasingly resistant to the conventional ... Wisconsin scientists has synthesized a potent new class of ... infections. , Writing online in the Journal of ... University of Wisconsin-Madison chemistry Professor Helen Blackwell describes agents ... Staphylococcus aureus , a bacterium at the root ...
(Date:5/22/2013)... improve durability in fuel cell powered buses, including ... links between electrode degradation processes and bus membrane ... of electrode degradation stressors in the operating cycle ... The findings of the study, led by SFU ... a long-term study at Burnaby-based Ballard Power Systems ...
(Date:5/22/2013)... Md. (May 22, 2013)The omega 3 fatty acids in ... cardiovascular diseaseso much so that the American Heart Association ... a week, particularly fatty varieties rich in omega 3s. ... a mystery. In a new study, scientists led by ... on this phenomenon by providing evidence that fish oil ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2
... 2009 News reports last week about scuba divers off ... jumbo squid have raised the ire of University of Rhode ... the species who has dived with them several times, he ... is seriously overblown. For years Seibel has heard stories ...
... In a study released online on July 22 in ... Sciences , researchers at Arizona State University and Princeton ... rationally than our multimodal, egg-headed, tool-using, bipedal, opposing-thumbed ... humans being "stupider" than ants. Humans and animals simply ...
... Researchers at the University of Texas Medical Branch at ... while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera ... that all women who use DMPA will gain weight and ... whose weight increased by 5 percent within the first six ...
Cached Biology News:URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 2URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 3Ants more rational than humans 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2
... Gene Knockout System provides optimized reagents and ... of bacterial genes by insertion of group ... ability of group II introns and utilizes ... TargeTron group II intron for specific insertion ...
...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
Biology Products: